Loading cancer entity…
Loading cancer entity…
Clinical trials
3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG)(MyDRUG) | completed | Phase 1 / Phase 2 | 103 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03792763 | Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients(DEFENCE) | completed | Phase 2 | 8 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Feb 11, 2025 |
| clinicaltrials |
| NCT03398200 | Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma | completed | Phase 2 | 99 | Omar AljitawiOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03762291 | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine(MAPSS) | completed | Phase 1 | 1 | Baylor College of MedicineOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01539083 | Velcade (Bortezomib) Consolidation After Transplant(VCAT) | completed | Phase 3 | 256 | Janssen Scientific Affairs, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT02874742 | Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 224 | Janssen Research & Development, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 10 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05986682 | Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | — | 30 | Duke UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03187223 | Bendamustine and Melphalan in Myeloma(BEB-2) | completed | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT01718743 | Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04634435 | Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients | completed | Phase 1 | 7 | Biohaven Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT03870633 | Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma | completed | — | 521 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04135079 | Immune Profiling in Multiple Myeloma | completed | — | 50 | Mario BoccadoroOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05393024 | Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy | completed | — | 78 | Fondazione EMN Italy OnlusOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04191057 | Determining Normal Range for Free Light Chains in Serum Among Twins | completed | N/A | 32 | University of California, San FranciscoOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | Wake Forest University Health SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT01903811 | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | completed | Phase 2 | 143 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | completed | Phase 2 | 38 | Zwi BernemanOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03848676 | Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma | completed | — | 40 | University of Turin, ItalyOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04137523 | Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression | completed | — | 26 | University of Turin, ItalyOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT01919619 | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | completed | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04436029 | Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | completed | Phase 2 | 5 | Cartesian TherapeuticsINDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05896774 | A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China | completed | Phase 1 | 10 | PfizerINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | completed | Phase 3 | 656 | TakedaINDUSTRY | 33 | Nov 19, 2024 | clinicaltrials |
| NCT03006315 | Mobile Health Device Study for Myeloma Patients | completed | — | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03233776 | Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT(AFFECT-1) | completed | Phase 2 | 9 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04099901 | Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial(AFFECT-2) | completed | Phase 2 | 88 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT01857115 | Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)(wCCyd) | completed | Phase 1 / Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02043847 | TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)(BMT-03) | completed | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | completed | Phase 1 | 20 | Noah MerinOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT00482261 | A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression | completed | Phase 2 | 150 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT01093196 | Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients | completed | Phase 3 | 660 | Fondazione EMN Italy OnlusOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01755975 | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01091831 | Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects | completed | Phase 3 | 389 | Fondazione EMN Italy OnlusOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05260203 | MargheRITA (Remote Intelligence for Therapeutic Adherence)(MargheRITA) | completed | N/A | 124 | Advice Pharma Group srlINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05567887 | A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies | completed | Phase 1 | 7 | PfizerINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03399539 | Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma | completed | Phase 1 | 8 | Mayo ClinicOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04398485 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 23 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05932290 | A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | completed | — | 514 | PfizerINDUSTRY | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04615572 | Screening to Improve Survival in AL Amyloidosis | completed | — | 35 | Tufts Medical CenterOTHER | 1 | Oct 28, 2024 | clinicaltrials |
| NCT03595800 | Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen(HaploMUD-RIC) | completed | Phase 3 | 9 | Institut Paoli-CalmettesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT00747123 | A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02294487 | Study of the Immune Response After Vaccination in Multiple Myeloma Patients | completed | — | 19 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 14, 2025source: clinicaltrials